The future of biomanufacturing is cell-free

Chemicals are everywhere around us. They're in our medicine, fuel, plastic, food, and most colors, to name a few applications. Biochemical extraction is often inefficient, and petrochemical production is toxic and polluting. However - for the first time in history – we now have the tools and insight to control and optimize nature’s own biological processes, enabling us to replace traditional chemical production methods with a sustainable and eco-friendly alternative: Exozymes.

Exozymes are advanced enzymes engineered using AI to thrive cell-free in a bioreactor. Exozyme biosolutions allow us to efficiently transform affordable and widely available feedstocks into a diverse range of valuable small-molecule chemicals, including active pharmaceutical ingredients, and nutraceuticals.

Three complementary commercialization pathways

Spin-Outs

Spin-outs are used when an opportunity supports the creation of a focused, standalone company with significant long-term value potential. In these cases, eXoZymes contributes proprietary technology, process know-how, and intellectual property, while the spin-out raises dedicated capital and builds an independent operating team.

This structure allows eXoZymes to retain meaningful equity exposure and upside, while limiting balance-sheet risk and preserving internal focus.

Joint-Ventures

Joint ventures are employed when strategic partners provide market access, infrastructure, or domain expertise that materially accelerates commercialization. In these structures, eXoZymes combines its platform and IP with a partner’s operational capabilities, allowing risk, capital requirements, and upside to be shared.

Joint ventures enable faster scaling and strong alignment between technology ownership and downstream execution.

Licensing

Licensing is used when partners are best positioned to commercialize an asset directly. eXoZymes licenses process technology, enzyme systems, or molecule-specific rights in exchange for upfront payments, milestones, royalties, or a combination thereof.

This pathway allows eXoZymes to monetize its platform at scale while remaining operationally lean and capital efficient.

How is value created in the spin-outs, joint-ventures, and licensing deals?

We focus on rapidly advancing high-impact assets through clearly defined value inflection points, each designed to mitigate risk, validate our platform, and unlock commercial opportunity.

With a high-throughput process for early wins and a clear path to monetization, we’re positioned to deliver accelerated returns at the intersection of industrial biotechnology and strategic partnering. By progressing quickly and strategically through each step, we maximize returns for shareholders, attract world-class partners, and accelerate our mission of transforming chemical manufacturing.

Note: This is our current version, but this can be updated over time.

Value Inflection Points: De-risking Innovation

Ideation

We identify unique problems where our exozyme biosolutions offers a differentiated solution with a strong technical and market fit. Thanks to our idea management process, promising opportunities emerge rapidly.

Proof of Concept

Typically in weeks, we can validate that we can produce the desired compound using an AI-engineered pathway of exozymes. This process moves faster than traditional platforms, compressing timelines and reducing capital exposure.

Optimization & Technical Validation

We optimize the exozyme pathways to demonstrate robust, repeatable yields -generating the data needed for asset valuation and early-stage partner engagement.

Scale-Up Demonstration

Technical success is expanded to 10x–100x scale, proving industrial viability. Strategic partners are brought in here to co-invest in scale-up and go-to-market, minimizing CapEx and execution risk for eXoZymes and our shareholders.

Commercialization & Deal Structuring

We convert validated opportunities into structured deals – spin-outs, joint-ventures, or licensing - each tailored to maximize equity value and preserve long-term upside. We work with partners to quantify economic value based on performance metrics, projected cost of goods, and market positioning—establishing fair and scalable value-sharing models.